Evaluating the FloStent for treating symptoms of benign prostatic hyperplasia in men

A Prospective, Multicenter, Double Blind, Randomized, Clinical Study to Evaluate the Safety and Efficacy of The FloStent in Men Suffering From Benign Prostatic Hyperplasia Symptoms

Not applicable Interventional Rivermark Medical · NCT06849258

This study is testing whether the FloStent can help men over 45 with symptoms of benign prostatic hyperplasia feel better compared to a fake procedure.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment215 (estimated)
Ages45 Years and up
SexMale
SponsorRivermark Medical Industry-sponsored
Locations20 sites (Bakersfield, California and 19 other locations)
Trial IDNCT06849258 on ClinicalTrials.gov

What this trial studies

This clinical study aims to assess the safety and efficacy of the FloStent, a medical device designed to alleviate symptoms associated with benign prostatic hyperplasia (BPH). Male participants over 45 years old with symptomatic BPH will be randomly assigned to receive either the FloStent or a sham procedure, which does not involve the deployment of the device. All participants will undergo a flexible cystoscopy as part of the evaluation process. The study will compare outcomes between the treatment and control groups to determine the effectiveness of the FloStent.

Who should consider this trial

Good fit: Ideal candidates for this study are men over 45 years old who experience significant symptoms of BPH.

Not a fit: Patients with prior prostate interventions, certain medical conditions, or those in vulnerable populations may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new, effective treatment option for men suffering from BPH symptoms.

How similar studies have performed: While the FloStent approach is relatively novel, similar studies evaluating device-based treatments for BPH have shown promising results.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male subjects \> 45 years of age who have symptomatic BPH
* International Prostate Symptom Score (IPSS) score \>13
* Peak urinary flow rate (Qmax): \>5 mL/sec and \<13 mL/sec with minimum voided volume of \>125 mL
* Post-void residual (PVR) \<250 mL
* Prostate volume 25 to 80 mL
* Prostatic urethral length 20-50 mm
* Able to complete the study protocol and visits

Exclusion Criteria:

* Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate
* Prior minimally invasive intervention or surgical intervention of the prostate or urethra
* PSA \>10 ng/mL
* Bladder cancer or bladder stones
* Active urinary tract infection (UTI)
* Uncontrolled diabetes
* Part of a vulnerable population (cognitively challenged or are incarcerated)

Where this trial is running

Bakersfield, California and 19 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Benign Prostatic Hyperplasiabenign prostatic hyperplasiaFloStentRivermark MedicalBPHLUTSLower urinary tract symptomsenlarged prostate
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.